FDA gives immunotherapy drug Tecentriq approval to treat breast cancer

Credit: DaytonDailyNews

caption arrowCaption
What You Need to Know: Breast Cancer

Credit: DaytonDailyNews

The first immunotherapy drug has been approved by the Food and Drug Administration to treat breast cancer.

Tecentriq was approved Friday for treating advanced triple-negative breast cancer, The Associated Press reported.

Triple-negative accounts for about 15 percent of cases of breast cancer.

Tecentriq will accompany the usual treatment of chemotherapy and will help increase the immune system's ability to find and kill cancer cells, according to the AP.

>> Read more trending news

Nine hundred women were studied for the Tecentriq treatment.

Those who had the drug had two months where cancer didn’t get worse, compared to patients who just had chemotherapy. But there were side effects with the combination treatment, including nerve pain and nausea.

For more on how the drug was tested, click here.

Tecentriq costs about $13,400 a month, the AP reported.

caption arrowCaption
Detail of breast cancer cells. Breast cancer is a malignant growth that begins in the tissues of the breast.

Credit: American Cancer Society/Getty Images

Detail of breast cancer cells. Breast cancer is a malignant growth that begins in the tissues of the breast.

Credit: American Cancer Society/Getty Images

caption arrowCaption
Detail of breast cancer cells. Breast cancer is a malignant growth that begins in the tissues of the breast.

Credit: American Cancer Society/Getty Images

Credit: American Cancer Society/Getty Images

About the Author